Literature DB >> 9253108

Mechanisms of the graft-versus-leukemia reaction.

A J Barrett1.   

Abstract

It is now clear that the graft-versus-leukemia (GVL) effect which accompanies allogeneic bone marrow transplantation for hematological malignancies is a powerful therapeutic weapon which, if harnessed, could improve our ability to treat refractory malignant disorders. Advances in the understanding of the alloimmune response now provide a clearer picture of the mechanisms involved in the GVL reaction: the CD4+ T cell plays a central role in the orchestration of leukemia cell killing. The immunogenicity of the leukemia is also a major factor determining the effectiveness of the GVL response. The characterization of antigens restricted to leukemia and hematopoietic tissues should make it eventually possible to produce specific and powerful antileukemic alloresponses in donor lymphocytes by adoptive immunotherapy or by vaccines.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9253108     DOI: 10.1002/stem.150248

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  18 in total

1.  The clinical implications of mixed lymphocyte reaction with leukemic cells.

Authors:  Hee-Je Kim; Tai-Gyu Kim; Hyun Il Cho; Hoon Han; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

Authors:  T Teshima; G R Hill; L Pan; Y S Brinson; M R van den Brink; K R Cooke; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 3.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

4.  Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Authors:  Menachem Bitan; Lola Weiss; Michael Zeira; Eyal Zcharia; Shimon Slavin; Arnon Nagler; Israel Vlodavsky
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

5.  Chronic GvHD decreases antiviral immune responses in allogeneic BMT.

Authors:  Mohammad S Hossain; John D Roback; Brian P Pollack; David L Jaye; Amelia Langston; Edmund K Waller
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

6.  Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors.

Authors:  Cristian Carvallo; Richard Childs
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

7.  Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.

Authors:  Haesook T Kim; Conner J Shaughnessy; Sharmila C Rai; Carol Reynolds; Vincent T Ho; Corey Cutler; John Koreth; Mahasweta Gooptu; Rizwan Romee; Sarah Nikiforow; Philippe Armand; Edwin P Alyea; Joseph H Antin; Catherine J Wu; Robert J Soiffer; Jerome Ritz; Jennifer R Brown
Journal:  Blood Adv       Date:  2020-09-08

8.  Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.

Authors:  Marilène Binsfeld; Yves Beguin; Ludovic Belle; Eléonore Otjacques; Muriel Hannon; Alexandra Briquet; Roy Heusschen; Pierre Drion; Jenny Zilberberg; Bjarne Bogen; Frédéric Baron; Jo Caers
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

Review 9.  T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome.

Authors:  Ahmed Gaballa; Mikael Sundin; Arwen Stikvoort; Muhamed Abumaree; Mehmet Uzunel; Darius Sairafi; Michael Uhlin
Journal:  Int J Mol Sci       Date:  2016-10-11       Impact factor: 5.923

10.  Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.

Authors:  Ji-Young Lim; Da-Bin Ryu; Sung-Eun Lee; Gyeongsin Park; Eun Young Choi; Chang-Ki Min
Journal:  Mol Cells       Date:  2015-11-10       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.